Rapamycin - Effects on Alzheimer's and Cognitive Health
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Alzheimer Disease
- Mild Cognitive Impairment
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: placebo controlled studyMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Quadruple-blindPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 55 years and 89 years
- Gender
- Both males and females
Description
The study will consist of a screening/baseline period of up to 90 days pre-study drug, with a 12-month (+3 day) treatment period with rapamycin, followed by a post-treatment assessment completed within 14 days of the final study drug dose, and a final assessment conducted 6-months (+14 days) after t...
The study will consist of a screening/baseline period of up to 90 days pre-study drug, with a 12-month (+3 day) treatment period with rapamycin, followed by a post-treatment assessment completed within 14 days of the final study drug dose, and a final assessment conducted 6-months (+14 days) after the final study drug dose. The study duration is not expected to exceed 90 weeks for participants.
Tracking Information
- NCT #
- NCT04629495
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Sudha J Seshadri, MD UT Health San Antonio Principal Investigator: Mitzi J Gonzales, PhD UT Health San Antonio
Get Well Soon